Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study
Authors:
- Oliver GrossOGOliver Gross
- Onnen MoererOMOnnen Moerer
- Thomas RauenTRThomas Rauen
- Jan BöckhausJBJan Böckhaus
- Elion HoxhaEHElion Hoxha
- Achim JörresAJAchim Jörres
- Matthias KammMKMatthias Kamm
- Amin ElfanishAEAmin Elfanish
- Wolfram WindischWolfram Windisch
- Michael DreherMichael Dreher
- Juergen FloegeJFJuergen Floege
- Stefan KlugeSKStefan Kluge
Open Access
- 9 July 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (14) , 3049
Abstract
In COVID-19, guidelines recommend a urinalysis on hospital admission as SARS-CoV-2 renal tropism, post-mortem, was associated with disease severity and mortality. Following the hypothesis from our pilot study, we now validate an algorithm harnessing urinalysis to predict the outcome and the need for ICU resources on admission to hospital. Patients were screened for urinalysis, serum albumin (SA) and antithrombin III activity (AT-III) obtained prospectively on admission. The risk for an unfavorable course was categorized as (1) “low”, (2) “intermediate” or (3) “high”, depending on (1) normal urinalysis, (2) abnormal urinalysis with SA ≥ 2 g/dL and AT-III ≥ 70%, or (3) abnormal urinalysis with SA or AT-III abnormality. Time to ICU admission or death served as the primary endpoint. Among 223 screened patients, 145 were eligible for enrollment, 43 falling into the low, 84 intermediate, and 18 into high-risk categories. An abnormal urinalysis significantly elevated the risk for ICU admission or death (63.7% vs. 27.9%; HR 2.6; 95%-CI 1.4 to 4.9; p = 0.0020) and was 100% in the high-risk group. Having an abnormal urinalysis was associated with mortality, a need for mechanical ventilation, extra-corporeal membrane oxygenation or renal replacement therapy. In conclusion, our data confirm that COVID-19-associated urine abnormalities on admission predict disease aggravation and the need for ICU (ClinicalTrials.gov number NCT04347824).Keywords
All Related Versions
Funding Information
- Deutsche Forschungsgemeinschaft (CRC1192, GR 1852/6-1)
- Bundesministerium für Forschung, Technologie und Raumfahrt (STOP-FSGS-01GM1518C)
This publication has 36 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Role of Antithrombin III and Tissue Factor Pathway in the Pathogenesis of SepsisCritical Care Clinics, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Idiopathic nephrotic syndrome in childrenThe Lancet, 2018